Back to the main directory
EarningsReview / Equity
- A soft spot in a hard place by BNP Paribas Exane
- China CYTS Tours (600138 CH) by HSBC
- Norcros - FY24 trading in line with expectations by Edison Investment Research
- Q1-24 results first take by BNP Paribas Exane
- VietNam Holding - Introducing redeemable shares by Edison Investment Research
- Non material data changes by BNP Paribas Exane
- Revised targets out of reach by BNP Paribas Exane
- TCS (TCS IN) by HSBC
- Valmet (Buy, TP: EUR30.00) - Soft legacy, inorganic support by DnB Markets
- Icelandic Salmon (Buy, TP: NOK185.00) - Below consensus for Q1e by DnB Markets
- Ørsted (Hold, TP: DKK405.00) - Anticipation for 2024 tender activity by DnB Markets
- Shelf Drilling North Sea (Buy, TP: NOK45.00) - Key contract win in the North Sea by DnB Markets
- NCAB (Hold, TP: SEK70.00) - Continued slow market by DnB Markets
- Alfa Laval (Buy, TP: SEK495.00) - Alfa Lavalicious by DnB Markets
- Atrium Ljungberg (Hold, TP: SEK200.00) - Cost control behind PFPM beat by DnB Markets
- Weekly news, topics & discussion by DnB Markets
- Peab (Sell, TP: SEK58.00) - Consensus too bullish, too soon by DnB Markets
- Ncc (Buy, TP: SEK150.00) - Q1 was cold by DnB Markets
- Danske Bank (DANSKE DC) by HSBC
- Jiangsu Expressway (177 HK/ 600377 CH) by HSBC
- Xvivo Perfusion - Building an organ transplant powerhouse by Danske Bank Equity Research
- More on Librela (2) by BNP Paribas Exane
- Northern lights at the end of the tunnel? by BNP Paribas Exane
- Initiation feedback: Feeling the heat by BNP Paribas Exane
- For Honor (of Kings) by BNP Paribas Exane
- 中青旅（600138 CH） by HSBC
- OSE Immunotherapeutics - Funding accelerates Tedopi clinical development by Edison Investment Research
- An introduction to PageGroup by BNP Paribas Exane
- Non material data changes by BNP Paribas Exane
- Waiting for the turning point by BNP Paribas Exane
- Funding package more than covers forecast requirements by BNP Paribas Exane
- Non material data changes by BNP Paribas Exane
- Hexagon (Buy, TP: SEK140.00) - FCF set to catalyse re-rating by DnB Markets
- Telia Company (Buy, TP: SEK35.00) - We expect a solid Q1 by DnB Markets
- Alimak (Hold, TP: SEK100.00) - Limited changes ahead of Q1 by DnB Markets
- Electrolux Professional (Hold, TP: SEK71.00) - Inventory step-up to weigh on Q1 by DnB Markets
- Embla Medical (Buy, TP: DKK39.00) - Q1 set to build momentum by DnB Markets
- Catella (Buy, TP: SEK35.00) - Upside potential on risk appetite by DnB Markets
- Vår Energi (Buy, TP: NOK40.00) - Decent start to the year by DnB Markets
- Sector title by DnB Markets
- Valuation and market update by DnB Markets
- Skanska (Buy, TP: SEK225.00) - Solid Q1 order intake expected by DnB Markets
- Stillfront Group (Buy, TP: SEK23.00) - In search of organic growth by DnB Markets
- Recovery gets underway, with caution by BNP Paribas Exane
- Zalando SE (ZAL GR) by HSBC
- Atrium Ljungberg - Sell/SEK 180 (190): A period of slow growth and structural challenges by Nordea
- A Not So Sweet Trend by BNP Paribas Exane
- Inchcape: Growth at a very attractive price by BNP Paribas Exane
- Iran-Israel set to further drive geo-political risk premium by BNP Paribas Exane
- M&A scenario analysis around a potential 2i acquisition by BNP Paribas Exane